Ultrasound-Targeted Microbubble Cavitation with Sodium Nitrite Synergistically Enhances Nitric Oxide Production and Microvascular Perfusion

Microvascular obstruction is a common repercussion of percutaneous coronary intervention for distal microembolization, ischemia –reperfusion injury and inflammation, which increases post-myocardial infarction heart failure and mortality. Ultrasound-targeted microbubble cavitation (UTMC) may resolve microvascular obstruction while activating endothelial nitric oxide synthase (eNOS) and increasing endothelium-derived nitric oxide (NO) bioavailability. Nitrite, a cardioprotective agent, offers an additional source of NO and potential synergy with UTMC.
Source: Ultrasound in Medicine and Biology - Category: Radiology Authors: Tags: Original Contribution Source Type: research

Related Links:

Publication date: Available online 20 January 2020Source: Artificial Intelligence in MedicineAuthor(s): Oh Shu Lih, V Jahmunah, Tan Ru San, Edward J Ciaccio, Toshitaka Yamakawa, Masayuki Tanabe, Makiko Kobayashi, Oliver Faust, U Rajendra AcharyaAbstractCardiovascular disease (CVD) is the leading cause of death worldwide, and coronary artery disease (CAD) is a major contributor. Early-stage CAD can progress if undiagnosed and left untreated, leading to myocardial infarction (MI) that may induce irreversible heart muscle damage, resulting in heart chamber remodeling and eventual congestive heart failure (CHF). Electrocardiog...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
The field of medical AI is buzzing. More and more companies set the purpose to disrupt healthcare with the help of artificial intelligence. Given how fast these companies come and go, it can prove to be hard to stay up-to-date with the most promising ones. Here, I collected the biggest names currently on the market ranging from start-ups to tech giants to keep an eye on in the future. To further help you keep up with what A.I. brings to medicine, The Medical Futurist team made an easy-to-digest e-book about just that. I highly encourage you to read it and would love to hear about your thoughts! Artificial Intelligence has ...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Artificial Intelligence Healthcare Design AI digital health genetics Innovation Personalized medicine pharma GC1 big data drug development healthcare companies medical imaging Source Type: blogs
AbstractCardiovascular diseases, including hypertension, congestive heart failure, myocardial infarction, stroke and atherosclerosis, are common in patients with chronic kidney disease. Aside from the standard biomarkers, measured to determine cardiovascular risk, new ones have emerged: markers of oxidative stress, apoptosis, inflammation, vascular endothelium dysfunction, atherosclerosis, organ calcification and fibrosis. Unfortunately, their utility for routine clinical application remains to be elucidated. A causal relationship between new markers and cardiovascular diseases in patients with chronic kidney disease remai...
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 15 January 2020Source: Canadian Journal of CardiologyAuthor(s): Ming-Jer Hsieh, Cheng-Hung Lee, Ming-Lung Tsai, Chang-Fu Kao, Wen-Ching Lan, Yu-Tung Huang, Wen-Yi Tseng, Ming-Shien Wen, Shang-Hung ChangAbstractBackgroundTumor necrosis factor inhibitors (TNFi) improve joints outcomes and reduce cardiovascular (CV) risk in patients with rheumatoid arthritis (RA). However, 20-45% of RA patients are TNFi poor responders and have a significantly higher risk of CV events. In these TNFi non-responders, the use of second-line biological agents to improve synovial outcomes is supported by clinical...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
AbstractAimsTo develop a risk model for sudden cardiac death (SCD) in high ‐risk acute myocardial infarction (AMI) survivors.Methods and resultsData from the Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction trial (CAPRICORN) and the Valsartan in Acute Myocardial Infarction Trial (VALIANT) were used to create a SCD risk model (with non ‐SCD as a competing risk) in 13 202 patients. The risk model was validated in the Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study (EPHESUS). The rate of SCD was 3.3 (95% confidence interval 3.0–3.5) per ...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
CONCLUSIONS: In individuals with CKD, prediabetes was not associated with composite renal outcome, but was associated with an increased risk of proteinuria progression and adverse CV outcomes. PMID: 31943096 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
Publication date: Available online 15 January 2020Source: Journal of Photochemistry and Photobiology B: BiologyAuthor(s): Rui Si, Chao Gao, Rui Guo, Chen Lin, Jiayi Li, Wenyi GuoAbstractAcute Myocardial Infarction (MI) is one of the foremost causes of human death worldwide and it leads to mass death of cardiomyocytes, interchanges of unfavorable biological environment and affecting electrical communications by fibrosis scar formations, and specifically deficiency of blood supply to heart which leads to heart damage and heart failure. Recently, numerous appropriate strategies have been applied to base on solve these problem...
Source: Journal of Photochemistry and Photobiology B: Biology - Category: Speech-Language Pathology Source Type: research
CONCLUSIONS: Secondary adherence to beta-blockers improves 1-year prognosis after STEMI with preserved left ventricular function. PMID: 31932044 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
Studies have revealed a robust and independent correlation between chronic kidney disease (CKD) and cardiovascular (CV) events, including death, heart failure, and myocardial infarction. Recent clinical trials extend this range of adverse CV events, including malignant ventricular arrhythmias and sudden cardiac death (SCD). Moreover, other studies point out that cardiac structural and electrophysiological changes are a common occurrence in this population. These processes are likely contributors to the heightened hazard of arrhythmias in CKD population and may be useful indicators to detect patients who are at a higher SCD...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
AbstractPurpose of ReviewDespite major advances in terms of prevention, diagnosis, risk-stratification, management and rehabilitation, atherosclerosis and atherothrombosis continue to have major morbidity and mortality implications worldwide. Since the unraveling of the pivotal role of inflammation in atherothrombosis pathophysiology, several focused treatments have been proposed with the ultimate goal of preventing or treating myocardial infarction, stroke, and peripheral artery disease. In particular, given the centrality of interleukin-1 (IL-1), targeted anti-IL-1 agents have attracted substantial attention and efforts....
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
More News: Angioplasty | Biology | Cardiology | Coronary Angioplasty | Heart | Heart Attack | Heart Failure | Percutaneous Coronary Intervention | Perfusion | Radiology | Sodium | Ultrasound